The first published study of intravenous BPC-157 in humans found no adverse effects in two adults receiving 10–20 mg doses, though the sample is far too small for definitive safety conclusions.
0 adverse effectsNeither participant experienced any side effects from IV BPC-157 at doses up to 20 mg — the first formal safety data for this route of administration in humans, though based on only two people.
What the researchers found
Intravenous BPC-157 at doses of 10 mg and 20 mg was well-tolerated in two healthy adults with no adverse effects. Blood work monitoring showed no measurable effects on heart, liver, kidney, thyroid, or blood glucose biomarkers across the three-day study period.
This is the first published study examining intravenous BPC-157 administration in humans. Both participants had previously received IV BPC-157, and the IRB-approved protocol used escalating doses over two consecutive days.
Why it matters
BPC-157 is one of the most widely discussed peptides in the wellness and biohacking community, yet virtually all published research has been in animals. The near-complete absence of human data has been the elephant in the room. This tiny pilot study from Dr. Edwin Lee — one of very few researchers publishing human BPC-157 data — provides the first formal safety assessment of intravenous administration. While far too small to be definitive, it's a step toward filling the massive evidence gap between animal studies and widespread human use.
The numbers in context
n=2 · 10 mg IV on day 1 · 20 mg IV on day 2 · 250 cc normal saline · 1-hour infusions · 0 adverse effects reported · no changes in heart, liver, kidney, thyroid, or glucose markers
How the study worked
IRB-approved pilot safety study. Two participants had baseline blood work and vital signs recorded, then received 10 mg BPC-157 in 250 cc saline IV over one hour on day 1, followed by 20 mg on day 2. Fasting blood work and vitals were repeated on days 2 and 3. Participants were questioned about side effects at each visit.
Who was studied
2 healthy adults: a 58-year-old Asian male and a 68-year-old Caucasian female, both with prior IV BPC-157 experience
What this study cannot tell us
Extremely small sample (n=2) — essentially an anecdotal safety observation, not a powered study. Both participants had prior IV BPC-157 exposure, so truly naïve reactions weren't captured. Only three days of monitoring — no long-term safety data. Published in an alternative medicine journal, not a high-impact clinical journal. No control group. The doses used may not reflect typical clinical applications.
How to read the evidence
Preliminary evidence: an IRB-approved pilot study that is formally published but limited to 2 participants with no control group. Too small to establish safety definitively, but notable as the first published data on IV BPC-157 in humans.
When this study was published
Published in 2025, this is among the most recent human BPC-157 data available. Given the near-total absence of prior human IV data, even this tiny study fills a significant gap.
The bigger picture
BPC-157 has an enormous gap between its animal research base (hundreds of studies showing healing, anti-inflammatory, and protective effects) and its human evidence (almost none). This pilot study, while tiny, represents a meaningful step because it's IRB-approved, formally published, and specifically tests the safety of intravenous administration — the most aggressive route. Dr. Lee's group is essentially the only team publishing human BPC-157 data, making each study significant by default in a field starving for human evidence.
Questions still open
- Will larger, controlled studies confirm the safety of IV BPC-157 at these or higher doses?
- What are the pharmacokinetics of IV BPC-157 — how long does it stay in the body and where does it go?
- Beyond safety, does IV BPC-157 show measurable therapeutic effects in humans that match the animal data?
Common questions
Is this study enough to prove IV BPC-157 is safe?
Why is this study significant if it only has two participants?
Read the original research
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Alternative therapies in health and medicine, 31(5), 20-24
Citation
Lee, Edwin; Burgess, Kailynd. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.. Alternative therapies in health and medicine, 31(5), 20-24.